We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
- Authors
Goldstein, Lori J; O'Neill, Anne; Sparano, Joseph A; Perez, Edith A; Shulman, Lawrence N; Martino, Silvana; Davidson, Nancy E
- Abstract
The combination of doxorubicin and cyclophosphamide (AC) is a standard adjuvant regimen. Doxorubicin and docetaxel (AT) is one of the most active cytotoxic regimens for metastatic breast cancer. The purpose of this trial was to determine whether adjuvant AT improved disease-free survival compared with AC in operable breast cancer.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 25, p4092
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.16.7841